146 related articles for article (PubMed ID: 25713431)
1. Oral bisphosphonate use and risk of postmenopausal endometrial cancer.
Newcomb PA; Passarelli MN; Phipps AI; Anderson GL; Wactawski-Wende J; Ho GY; O'Sullivan MJ; Chlebowski RT
J Clin Oncol; 2015 Apr; 33(10):1186-90. PubMed ID: 25713431
[TBL] [Abstract][Full Text] [Related]
2. Oral bisphosphonate use and lung cancer incidence among postmenopausal women.
Tao MH; Chen S; Freudenheim JL; Cauley JA; Johnson KC; Mai X; Sarto GE; Wakelee H; Boffetta P; Wactawski-Wende J
Ann Oncol; 2018 Jun; 29(6):1476-1485. PubMed ID: 29617712
[TBL] [Abstract][Full Text] [Related]
3. Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative.
Passarelli MN; Newcomb PA; LaCroix AZ; Lane DS; Ho GY; Chlebowski RT
J Bone Miner Res; 2013 Sep; 28(9):2043-8. PubMed ID: 23519920
[TBL] [Abstract][Full Text] [Related]
4. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
6. The effect of bisphosphonates on the risk of endometrial and ovarian malignancies.
Rennert G; Rennert HS; Pinchev M; Lavie O
Gynecol Oncol; 2014 May; 133(2):309-13. PubMed ID: 24556062
[TBL] [Abstract][Full Text] [Related]
7. Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative.
Drieling RL; LaCroix AZ; Beresford SA; Boudreau DM; Kooperberg C; Chlebowski RT; Gass M; Crandall CJ; Womack CR; Heckbert SR
Menopause; 2016 Nov; 23(11):1168-1175. PubMed ID: 27433859
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate use and the risk of endometrial cancer: a meta-analysis of observational studies.
Ou YJ; Chiu HF; Wong YH; Yang YH
Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1107-1115. PubMed ID: 27501339
[TBL] [Abstract][Full Text] [Related]
9. Oral bisphosphonate use and breast cancer incidence in postmenopausal women.
Chlebowski RT; Chen Z; Cauley JA; Anderson G; Rodabough RJ; McTiernan A; Lane DS; Manson JE; Snetselaar L; Yasmeen S; O'Sullivan MJ; Safford M; Hendrix SL; Wallace RB
J Clin Oncol; 2010 Aug; 28(22):3582-90. PubMed ID: 20567009
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of bisphosphonates on endometrial cancer incidence in data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.
Alford SH; Rattan R; Buekers TE; Munkarah AR
Cancer; 2015 Feb; 121(3):441-7. PubMed ID: 25533883
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
[TBL] [Abstract][Full Text] [Related]
12. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008.
Siris ES; Pasquale MK; Wang Y; Watts NB
J Bone Miner Res; 2011 Jan; 26(1):3-11. PubMed ID: 20662073
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women.
Margolis KL; Rodabough RJ; Thomson CA; Lopez AM; McTiernan A;
Arch Intern Med; 2007 Sep; 167(17):1837-44. PubMed ID: 17893304
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature.
Liu Y; Zhao S; Chen W; Hu F; Zhu L; Zhang Q; Zhao Y
Clin Breast Cancer; 2012 Aug; 12(4):276-81. PubMed ID: 22622199
[TBL] [Abstract][Full Text] [Related]
15. Is Endometrial Cancer Risk Reduced by Oral Bisphosphonate Use?
Tomao F; Colombo N; Panici B
J Clin Oncol; 2015 Nov; 33(31):3670. PubMed ID: 26282662
[No Abstract] [Full Text] [Related]
16. Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis.
Zhang XS; Zhang YM; Li B; Fan B; Zhao Y; Yang SJ
Gynecol Oncol; 2018 Sep; 150(3):509-514. PubMed ID: 29960711
[TBL] [Abstract][Full Text] [Related]
17. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
Sebba AI
Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
[TBL] [Abstract][Full Text] [Related]
18. Tubal Ligation and Risk of Endometrial Cancer: Findings From the Women's Health Initiative.
Winer I; Lehman A; Wactawski-Wende J; Robinson R; Simon M; Cote M
Int J Gynecol Cancer; 2016 Mar; 26(3):464-71. PubMed ID: 26825831
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference.
Costa L
Curr Opin Support Palliat Care; 2014 Dec; 8(4):414-9. PubMed ID: 25319273
[TBL] [Abstract][Full Text] [Related]
20. Use of bisphosphonates and risk of postmenopausal breast cancer.
Rennert G; Pinchev M; Rennert HS
J Clin Oncol; 2010 Aug; 28(22):3577-81. PubMed ID: 20567021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
